

**REMARKS**


Entry of the foregoing amendments are respectfully requested.

Should the Examiner have any questions concerning the subject application, a telephone call to the undersigned would be appreciated.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: \_\_\_\_\_

  
Teresa Stanek Rea  
Registration No. 30,427

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620

**Date: March 29, 2002**

**Attachment to Preliminary Amendment dated March 29, 2002**

**Marked-up Claims 1 - 8**

1. (Amended) [Pharmaceutical preparation] A pharmaceutical composition comprising, separately or together, an efficacious amount of (i) loteprednol or a pharmaceutically tolerable ester thereof and (ii) at least one  $\beta_2$  adrenoceptor agonist for simultaneous, sequential or separate administration by inhalation in the treatment of airway disorders in mammals.

2. (Amended) [Pharmaceutical preparation] The pharmaceutical composition according to claim 1, [characterized in that] wherein the pharmaceutically tolerable ester of loteprednol is loteprednol etabonate.

3. (Amended) [Pharmaceutical preparation] The pharmaceutical composition according to claim 1 [or 2], [characterized in that] wherein the  $\beta_2$  adrenoceptor agonist is selected from the group consisting of salbutamol, reproterol, salmeterol, formoterol and their pharmaceutically tolerable salts.

4. (Amended) [Pharmaceutical preparation] The pharmaceutical composition according to [one of claims 1 to 3] claim 1, [characterized in that it contains] which comprises (i) loteprednol and (ii) formoterol.

**Attachment to Preliminary Amendment dated March 29, 2002**

**Marked-up Claims 1 - 8**

5. (Amended) [Pharmaceutical preparation] The pharmaceutical composition according to [one of claims 1 to 3] claim 1, [characterized in that it contains] which comprises (i) loteprednol and (ii) salmeterol.

6. (Amended) [Pharmaceutical preparation] The pharmaceutical composition according to [one of claims 1 to 3] claim 1, [characterized in that it contains] which comprises (i) loteprednol and (ii) reproterol.

7. (Amended) [Medicament] A method for the treatment of allergies and/or airway disorders, comprising administering to a patient in need of such treatment an efficacious amount of (i) loteprednol and (ii) at least one  $\beta_2$  adrenoceptor agonist, if appropriate together with customary excipients or vehicles, for simultaneous, sequential or separate administration.

8. (Amended) [Process] A process for the [production of a medicament] preparation of a pharmaceutical composition for the treatment of allergies and/or airway disorders, comprising an effective amount of the active compound loteprednol and at least one  $\beta_2$  adrenoceptor agonist, [characterized in that] wherein loteprednol and the  $\beta_2$  adrenoceptor agonist or the  $\beta_2$  adrenoceptor agonists are mixed individually or together, if

**Attachment to Preliminary Amendment dated March 29, 2002**

**Marked-up Claims 1 - 8**

appropriate together with customary excipients or vehicles, and the mixture thus obtained is converted into suitable administration forms.